Computed tomography has been the most widely used modality for oncology imaging, but
the addition of positron emission tomography is raising the bar and making the fused
technologies the gold standard for imaging cancer patients.
The thought of having cancer can scare just about everyone. If there is
any positive side, it is that early detection, appropriate treatment and follow-up
monitoring of tumors will increase survival rates. Most critical is the first step
pinpointing the precise location of the suspected cancer.
Computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron
emission tomography (PET) have come to serve as valuable tools in oncology imaging. Each
modality has its attributes and shortcomings based on which region of the body cancer is
suspected.
In terms of procedure volume, CT has been and remains the most widely
used medical imaging modality to locate cancer initially. Over the past four years,
however, PET has captured the attention of oncologists and radiologists, spurred greatly
by the Centers for Medicare & Medicaid Services (CMS of Baltimore, Md.) actions
to reimburse PET imaging procedures for a growing number of oncology indications.
With CT providing the anatomical information and PET supplying the functional data, the
latest technology boost for oncology imaging is the fusing of PET and CT scans into one
image.
Please refer to the May 2002
issue for the complete story.
For information on article reprints, contact
Martin St. Denis